GRI Bio (GRI) FCF Margin (2020)
GRI Bio (GRI) posted quarterly FCF Margin of 768.0% for Q1 2020.
GRI Bio (GRI) FCF Margin (2020) Analysis & Trends
GRI Bio's FCF Margin history runs 1 years deep, the most recent figure standing at 768.0% for Q1 2020.
- In Q1 2020, FCF Margin changed N/A year-over-year to 768.0%; the TTM figure through Dec 2020 stood at 3708.0% (changed N/A YoY), while the FY2020 annual figure was 3708.0%, changed N/A from the prior year.
- FCF Margin for Q1 2020 stood at 768.0%.
- The five-year high for FCF Margin was 768.0% in Q1 2020, with the low at 768.0% in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 22.62% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -22.35% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 70.82% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 41.07% |
| 10 | GRI Bio | 3.07 Mn | 3.07 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -768.00% |